my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-13-2008: Galapagos NV announced that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB's medicinal chemistry programs. The total contract value for Galapagos could potentially exceed EUR4 M. Additionally, Galapagos is eligible to receive up to EUR500,000 in success payments subject to fulfillment of certain conditions.
UCB will transfer a team of chemists to BioFocus DPI from UCB's recently closed Cambridge (UK) research site and BioFocus DPI will continue the chemistry work for the program that was running at UCB, towards candidate selection stage. Under the contract, UCB will provide biology support for the program.
"This agreement with UCB demonstrates BioFocus DPI's flexibility in meeting client needs," said Chris Newton, Senior Vice President of BioFocus DPI. "This innovative deal structure allows UCB to progress their program externally while applying the specific project expertise that UCB has already built internally."
Watchlist
This is where you can add this news to your personal favourites
UCB transfers UK-based medicinal chemistry program to BioFocus DPI
Galapagos NV announced that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB's medicinal chemistry programs. The total contract value for Galapagos could potentially exceed EUR4 M. Additionally ... more
Pierre Fabre acquires Over-The-Counter Business of UCB in France, Benelux, Switzerland and Greece
Pierre Fabre and UCB jointly announce that Pierre Fabre has acquired the OTC business of UCB in France, Benelux, Switzerland and Greece. The acquisition involves certain mature products with strong brand names (a.o. Carbolevure, Revitalose, Balsoclase, Toclase), representing sales of approx ... more
Successful takevoer of Schwarz Pharma by UCB
UCB announces that it has received tenders amounting to 87.62% of the total outstanding share capital of SCHWARZ PHARMA AG (or 86.80% of the fully diluted share capital, including treasury shares) during its tender offer for SCHWARZ PHARMA which closed on December 28, 2006 at midnight. Shar ... more
Doris Hafenbradl joins BioFocus as Senior Director, Biology and Natural Products
BioFocus announced that Dr. Doris Hafenbradl has joined BioFocus as Senior Director, Biology and Natural Products, based in Basel, Switzerland. Doris joins BioFocus from Proteros Biostructures where, as Executive VP, she was responsible for the strategic business and scientific development ... more
BioFocus DPI and Procter & Gamble sign compound management agreement
BioFocus DPI announced that it has signed a three year compound management agreement with Procter & Gamble Co. (P&G). Under the agreement, BioFocus DPI will manage P&G’s chemical library collection. These services will be provided by BioFocus DPI’s compound management facility in South Sa ... more
Galapagos sells San Diego chemistry facility to ChemVentures
Galapagos NV announced that it has completed the sale of its BioFocus DPI chemistry facility in San Diego to ChemVentures Pty Ltd, an Australian discovery research group. Financial terms were not disclosed. The San Diego facility currently employs 40 people and provides medicinal chemist ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
